Chemspec Europe 2018 in Cologne closes wit... The 33rd edition of Chemspec Europe, International Exhibition for Fine and Speciality Chemicals, ended after two successful show days with record visitor numbers. From 20 to 21 June 2018, a total of … more ➔
Piglet vaccination to reduce antibiotics u...Researchers at VTT Technical Research Centre of Finland have developed a vaccine, diluted into drinking water, to treat diarrhoea on piglets being weaned. The vaccine is expected to reduce the global … more ➔
VarmX raises €12.5mVarmX will use the combination of a €7.5m Series A financing co-led by BioGeneration Ventures (BGV) and Dutch regional development company InnovationQuarter plus an €5m innovation credit from … more ➔
CHMP greenlights first two CAR-T cell ther...The EMA’s CHMP recommended nine medicines including six orphan medicines for EU market approval on Friday. more ➔
Improving models of chronic hepatitisGerman and US researchers have designed a mouse model that exactly mimics the mechanisms of hepatitis infection in men. more ➔
GMO acreage growing globallyAgribiotech lobby group ISAAA reports that global GMO acreage has grown to 189.8 million hectares in 2017 -3% or 4.7 million hectares more than in 2016. more ➔
Chugai ends licence for PharmaMar’s...Roche’s Japanese arm Chugai today returned all rights from a 2016 licence agreement on the RNA polymerase II blocker lurbinectedin to Spanish oncology specialist PharmaMar SA. more ➔
Inflammasome specialist NodThera Ltd raise...Selvita spin-out NodThera Ltd raised £28 million (€31.8m) in a Series A financing round led by Sofinnova Partners and 5AM Ventures and co-financed by Epidarex Capital and F-Prime Capital Partners … more ➔
Researchers identify T cell guardians of t...Special immune cells that protect the lining of the gut remain in a semi-active state, ready to fend off a pathogen at any moment, thanks to the composition of their mitochondrial membrane, a new study … more ➔
Afatinib push back K-RAS-positive lung can...A team of Austrian, Hungarian and Canadian researchers has demonstrated that Boehringer Ingelheim’s FDA-approved ERB family kinase blocker afatinib prolonged survival in hard-to-treat K-RAS-mutated lung … more ➔
